<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03648021</url>
  </required_header>
  <id_info>
    <org_study_id>MDY_2017_19</org_study_id>
    <nct_id>NCT03648021</nct_id>
  </id_info>
  <brief_title>The Effect of Paracetamol on Brain Temperature</brief_title>
  <acronym>NEUROTHERM</acronym>
  <official_title>NEUROTHERM: The Effect of Paracetamol on Brain Temperature in Acute Brain Injury in a Neuro Critical Care Unit: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare the effect of intravenous paracetamol
      administration on mean brain temperature (measured between H0 and H6) in patients with
      cerebral hyperthermia versus placebo.

      The investigators will measure brain temperature using a thermistor that will be connected to
      the intracranial pressure transducer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of mean brain temperature measured between H0 and H6 following administration of treatment between the two groups (the group treated with paracetamol and the placebo group)</measure>
    <time_frame>Six hours after administration of treatment</time_frame>
    <description>measurement of intracerebral temperature in degrees</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Brain Injuries</condition>
  <arm_group>
    <arm_group_label>paracetamol (acetaminophen)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient will receive1 gramme of paracetamol intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient will receive 100 ml of chlorure de sodium 0,9% intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>&gt;50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose
&gt;50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose</description>
    <arm_group_label>paracetamol (acetaminophen)</arm_group_label>
    <other_name>acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100mL of chlorure de sodium 0.9% administred intravenously. 1 dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  18-year or older patients

          -  Patient hospitalized in neuro-critical care for:

          -  Arachnoid hemorrhage

          -  Intra parenchymatous hematoma

          -  stroke

          -  Acute brain Severe injury

          -  Post-operative complication of an act of neurosurgery or programmed neuroradiology

          -  Sedation and mechanical ventilation planned &gt; 2 days

          -  Monitoring of intracranial temperature and pressure by intraparenchymal sensor
             (Sophysa®)

          -  Brain temperature &gt; 38.5°C for more than 30 minutes

        Exclusion Criteria

          -  Known hypersensitivity to paracetamol or mannitol (excipient with known effect)

          -  Severe hepatocellular insufficiency (ASAT or ALAT &gt; 5N, or bilirubin &gt; 2N)

          -  Pharmacological intervention (administration of corticosteroids, NSAIDs or
             paracetamol) or physical intervention (external cooling technique) that may influence
             temperature in the last 6 hours.

          -  Pregnant or breastfeeding women

          -  Previous participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marine de Mesmay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique Adolphe de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie YAVCHITZ, MD PhD</last_name>
    <phone>0033148036433</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie YAVCHITZ, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

